Compare SHPH & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHPH | GLMD |
|---|---|---|
| Founded | 2012 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 4.4M |
| IPO Year | 2022 | 2014 |
| Metric | SHPH | GLMD |
|---|---|---|
| Price | $1.63 | $0.64 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 7.5M | 63.7K |
| Earning Date | 02-25-2026 | 11-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.26 | $0.66 |
| 52 Week High | $19.75 | $3.50 |
| Indicator | SHPH | GLMD |
|---|---|---|
| Relative Strength Index (RSI) | 42.73 | 30.25 |
| Support Level | $1.91 | $0.66 |
| Resistance Level | $2.35 | $0.87 |
| Average True Range (ATR) | 0.47 | 0.05 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 8.30 | 4.70 |
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. It is developing a pipeline of products designed to address the limitations of the current cancer therapies as well as to extend to the new applications of RT. The company believes that its product candidates will enable the company to deliver cancer treatments that are safer, more reliable and at a greater scale than that of the current standard of care.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.